Therapeutic Options in Patients with Lymphoma and Severe Liver Dysfunction

Mayo Clinic Proceedings

Volumn 79, Issue 2, 2004, Pages 169-175

  Ghobrial, Irene M ^a   Wolf, Robert C ^a   Pereira, Denise L ^a,b   Fonseca, Rafael ^a   White, William L ^a   Colgan, Joseph P ^a   Habermann, Thomas M ^a   Inwards, David J ^a   Markovic, Svetomir N ^a   Ansell, Stephen M ^a   Micallef, Ivana N M ^a   Porrata, Luis F ^a   Witzig, Thomas E ^a  

^a Mayo Clinic   (United States)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BLEOMYCIN; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HODGKIN DISEASE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER BIOPSY; LIVER DISEASE; LIVER FUNCTION TEST; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; PROGNOSIS; REVIEW;

EID: 9144269623     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.2.169     Document Type: Article

References (33)

1. Bagley CM Jr, Thomas LB, Johnson RE, Chretien PB, DeVita VT Jr. Diagnosis of liver involvement by lymphoma: results in 96 consecutive peritoneoscopies. Cancer. 1973;31:840-847.
2. Birrer MJ, Young RC. Differential diagnosis of jaundice in lymphoma patients. Semin Liver Dis, 1987;7:269-277.
3. Cervantes F, Briones J, Bruguera M, et al. Hodgkin's disease presenting as a cholestatic febrile illness: incidence and main characteristics in a series of 421 patients. Ann Hematol. 1996;72:357-360.
4. Givler RL, Brunk SF, Hass CA, Gulesserian HP. Problems of interpretation of liver biopsy in Hodgkin's disease. Cancer. 1971;28:1335-1342.
5. Black M. Liver disease and drug therapy. Med Clin North Am. 1974;58:1051-1057.
6. Blaschke TF. Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet. 1977;2:32-44.
7. Bond WS. Clinical relevance of the effect of hepatic disease on drug disposition. Am J Hosp Pharm. 1978;35:406-414.
8. Koren G, Beatty K, Seto A, Einarson TR, Lishner M. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother. 1992;26:363-371.
9. Kaplan EL, Meier P, Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy; use of methylbis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders, JAMA. 1946;132:126-132.
11. Karnofsky DA. Summary of results obtained with nitrogen mustard in the treatment of neoplastic disease. Ann N Y Acad Sci. 1958;68:899-914.
12. Lowenbraun S, DeVita VT, Serpick AA. Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcoma. Cancer. 1970;25:1018-1025.
13. Jacobs EM, Peters FC, Luce JK, Zippin C, Wood DA. Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas. JAMA. 1968;203:392-398,
14. Lenhard RE Jr, Owens AH Jr. Recent advances in chemotherapy of lymphoma. Johns Hopkins Med J. 1967;121:136-140.
15. Bonadonna G, De Lena M, Lattuada A, Milani F, Monfardini S, Beretta G. Combination chemotherapy and radiotherapy in non-Hodgkin's lymphomata. Br J Cancer. 1975;31(suppl 2):481-488.
16. Rubin P. Comment: the non-Hodgkin's lymphomas. JAMA. 1973;223:175-178.
17. Carbone PP. Management of patients with non-Hodgkin's lymphoma. Arch Intern Med. 1973;131:455-459.
18. Stefanato CM, Reyes-Mugica M. Masked Hodgkin's disease: the pruriginous disguise [letter]. Pediatr Hematol Oncol. 1996;13:293-294.
19. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003;21:607-614.
20. Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia. 1995;9:2115-2118.
21. Norfolk DR, Child JA. Pulsed high dose oral prednisolone in relapsed or refractory multiple myeloma. Hematol Oncol. 1989;7:61-68.
22. Herishanu Y, Lishner M, Kitay-Cohen Y. The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine. Anticancer Drugs. 2002;13:177-179.
23. Grillo-Lopez AJ, Hedrick E, Rashford, M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol. 2002;29(1, suppl 2):105-112.
24. Yedibela S, Reck T, Niedobitek G, et al. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation. Transpl Int. 2003;16:197-201.
25. Crosbie OM, Crown JP, Nolan NP, Murray R, Hegarty JE. Resolution of paraneoplastic bile duct paucity following successful treatment of Hodgkin's disease. Hepatology. 1997;26:5-8.
26. Takauchi K, Kono H, Ito T, Zaima K, Okumoto S. A case of primary hepatic lymphoma successfully treated by THP-COP therapy [in Japanese]. Nippon Ronen Igakkai Zasshi. 2003;40:65-68.
27. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy-efficacy, safety, and pharmacologic basis of an intermittent single high-dose schedule. Cancer. 1974;33:19-27.
28. Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol. 1982;8:215-219.
29. Dobbs NA, Twelves CJ, Gregory W, Cruickshanka C, Richards MA, Rubens RD. Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Eur J Cancer. 2003;39:580-586.
30. Juma FD. Effect of liver failure on the pharmacokinetics of cyclophosphamide. Eur J Clin Pharmacol. 1984;26;591-593.
31. Donelli MG, Zucchetti M, Munzone E, D'Incalci M, Crosignani A. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer. 1998;34:33-46.
32. Skrabs C, Muller C, Agis H, Mannhalter C, Jager U. Treatment of HBV-carrying lymphoma patients with rituximab and CHOP: a diagnostic and therapeutic challenge [letter]. Leukemia. 2002;16:1884-1886.
33. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab [letter]. N Engl J Med. 2001;344:68-69.